ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform
Retrieved on:
Tuesday, April 26, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, NIH, Lists of diseases, Bacteria, Vaccine, Memory B cell, Program, Infection, Review, Technology, Commissariat, BCG, Antigen, Radiobiology, Forward-looking statement, Investment, Ministry of Social Affairs, Ministry, Iliad, Medical research, Private Securities Litigation Reform Act, Moral and National Education controversy, Environment, Whooping cough, Fast track (FDA), Disease, Lists of publishing companies, National Institute of Allergy and Infectious Diseases, Tuberculosis, Medicine, Behavior, Twitter, WHO, TB, National, Bharath Institute of Higher Education and Research, Industry, Virus, Pasteur Institute, Cancer, Link, CEA, Genomics, Pasteur Institute of Lille, Person, NIAID, Parasitism, Bordetella pertussis, Innovation, National Institute, Diabetes, Degenerative disease, Pharmaceutical industry, Research, Biology, Health
ILiADs B-Tech Vector Platform utilizes a proprietary attenuated Bordetella pertussis (B. pertussis) strain as an intranasal vaccine vector to express pathogen target antigens, inducing both systemic and respiratory mucosal immunologic responses.
Key Points:
- ILiADs B-Tech Vector Platform utilizes a proprietary attenuated Bordetella pertussis (B. pertussis) strain as an intranasal vaccine vector to express pathogen target antigens, inducing both systemic and respiratory mucosal immunologic responses.
- B-Tech Vector Platform vaccines have demonstrated immunogenicity in 8 peer-reviewed published pre-clinical studies targeting viruses, bacteria, and parasites.
- In addition to preclinical development of B-Tech Vector vaccines for TB and other targets, ILiAD continues to advance its BPZE1 pertussis vaccine through late-stage clinical development.
- ILiAD Biotechnologies is utilizing its B-Tech technology to develop next generation vaccines to prevent infectious diseases and improve lives.